EP3253866C0 - GENETICALLY MANIPULATED PRIMARY HEMATOPOETIC CELLS BY SLOW RELEASE OF NUCLEIC ACIDS USING NANOPARTICLES - Google Patents

GENETICALLY MANIPULATED PRIMARY HEMATOPOETIC CELLS BY SLOW RELEASE OF NUCLEIC ACIDS USING NANOPARTICLES

Info

Publication number: EP3253866C0
Authority: EP; European Patent Office
Prior art keywords: nanoparticles; primary; nucleic acids; slow release; genetically manipulated
Prior art date: 2015-02-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

EP16703150.9A

Other languages

German (de)

French (fr)

Other versions

EP3253866B1 (en

EP3253866A1 (en

Inventor

Fabien Delacote

Philipe Duchateau

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cellectis SA

Original Assignee

Cellectis SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-02-06

Filing date

2016-02-05

Publication date

2024-12-04

2016-02-05 Application filed by Cellectis SA filed Critical Cellectis SA

2017-12-13 Publication of EP3253866A1 publication Critical patent/EP3253866A1/en

2024-12-04 Application granted granted Critical

2024-12-04 Publication of EP3253866B1 publication Critical patent/EP3253866B1/en

2024-12-04 Publication of EP3253866C0 publication Critical patent/EP3253866C0/en

Status Active legal-status Critical Current

2036-02-05 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Immunology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Developmental Biology & Embryology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

EP16703150.9A 2015-02-06 2016-02-05 Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles Active EP3253866B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA201570072		2015-02-06
PCT/EP2016/052552 WO2016124765A1 (en)	2015-02-06	2016-02-05	Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles

Publications (3)

Publication Number	Publication Date
EP3253866A1 EP3253866A1 (en)	2017-12-13
EP3253866B1 EP3253866B1 (en)	2024-12-04
EP3253866C0 true EP3253866C0 (en)	2024-12-04

Family

ID=52473719

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16703150.9A Active EP3253866B1 (en)	2015-02-06	2016-02-05	Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles

Country Status (4)

Country	Link
US (1)	US20190024065A1 (en)
EP (1)	EP3253866B1 (en)
AU (1)	AU2016214301B2 (en)
WO (1)	WO2016124765A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014117121A1 (en)	2013-01-28	2014-07-31	St. Jude Children's Research Hospital, Inc.	A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
SG11201609118RA (en)	2014-05-15	2016-11-29	Univ Singapore	Modified natural killer cells and uses thereof
WO2016182959A1 (en)	2015-05-11	2016-11-17	Editas Medicine, Inc.	Optimized crispr/cas9 systems and methods for gene editing in stem cells
WO2016201047A1 (en)	2015-06-09	2016-12-15	Editas Medicine, Inc.	Crispr/cas-related methods and compositions for improving transplantation
CN110114461A (en)	2016-08-17	2019-08-09	博德研究所	Novel C RISPR enzyme and system
WO2018035387A1 (en) *	2016-08-17	2018-02-22	The Broad Institute, Inc.	Novel crispr enzymes and systems
WO2018064387A1 (en) *	2016-09-28	2018-04-05	Novartis Ag	Porous membrane-based macromolecule delivery system
CA3039924A1 (en) *	2016-10-11	2018-04-19	Stemgenics, Inc.	Nanoparticles functionalized with gene editing tools and related methods
AU2017347685B2 (en) *	2016-10-19	2023-08-03	Cellectis	TAL-effector nuclease (TALEN) -modified allogenic cells suitable for therapy
WO2018073391A1 (en) *	2016-10-19	2018-04-26	Cellectis	Targeted gene insertion for improved immune cells therapy
BR112019007715A2 (en)	2016-10-19	2019-07-09	Cellectis Sa	vectorized gene insertion for enhanced immune cell therapy
WO2018073393A2 (en) *	2016-10-19	2018-04-26	Cellectis	Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
CA3056439A1 (en)	2017-03-27	2018-10-04	National University Of Singapore	Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2018182511A1 (en)	2017-03-27	2018-10-04	National University Of Singapore	Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
PT3592379T (en) *	2017-03-31	2024-05-31	Cellectis Sa	Universal anti-cd22 chimeric antigen receptor engineered immune cells
EP3652312A1 (en)	2017-07-14	2020-05-20	Editas Medicine, Inc.	Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
JP7360174B2 (en)	2018-02-09	2023-10-12	ナショナルユニヴァーシティーオブシンガポール	Activated chimeric receptors and their use in natural killer cell immunotherapy
US20190269728A1 (en)	2018-03-02	2019-09-05	Sixfold Bioscience Ltd.	Compositions for delivery of cargo to cells
US12441787B2 (en)	2018-04-02	2025-10-14	National University Of Singapore	Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CN112543650A (en) *	2018-04-24	2021-03-23	利甘达尔股份有限公司	Methods and compositions for genome editing
CN111164068B (en) *	2018-08-21	2023-11-14	株式会社东芝	Biodegradable compounds, lipid particles, compositions containing lipid particles, and kits
CN118546960A (en)	2019-03-05	2024-08-27	恩卡尔塔公司	CD 19-directed chimeric antigen receptor and use thereof in immunotherapy
US12357704B2 (en)	2019-05-06	2025-07-15	Thomas Malcolm	Tailored hypoimmune nanovesicular delivery systems for cancer tumors
JP7630904B2 (en) *	2019-07-23	2025-02-18	株式会社東芝	Nucleic acid transfer carrier, nucleic acid transfer carrier set, nucleic acid transfer composition, and nucleic acid transfer method
WO2021220053A2 (en)	2020-04-27	2021-11-04	Sixfold Bioscience Ltd.	Compositions containing nucleic acid nanoparticles with modular functionality
US20230416786A1 (en)	2020-11-30	2023-12-28	Cellectis Sa	Use of aminoquinoline compounds for higher gene integration
WO2025181336A1 (en)	2024-03-01	2025-09-04	Cellectis Sa	Compositions and methods for hbb-editing in hspc

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1748796A4 (en) *	2004-03-05	2008-08-27	Univ Texas	MULTILAYER NANOMEDICINE DELIVERY SYSTEM AND METHOD
DK2417262T3 (en) *	2009-04-07	2015-06-22	Dow Agrosciences Llc	NANOPARTICALLY MEDICATED SUPPLY OF SEQUENCE-SPECIFIC NUCLEASES
US20150017136A1 (en) *	2013-07-15	2015-01-15	Cellectis	Methods for engineering allogeneic and highly active t cell for immunotherapy
KR102437522B1 (en) *	2012-05-25	2022-08-26	셀렉티스	Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
EP2893004B1 (en) *	2012-09-04	2018-10-24	Cellectis	Multi-chain chimeric antigen receptor and uses thereof
WO2014191128A1 (en) *	2013-05-29	2014-12-04	Cellectis	Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system

2016
- 2016-02-05 EP EP16703150.9A patent/EP3253866B1/en active Active
- 2016-02-05 AU AU2016214301A patent/AU2016214301B2/en active Active
- 2016-02-05 US US15/546,926 patent/US20190024065A1/en not_active Abandoned
- 2016-02-05 WO PCT/EP2016/052552 patent/WO2016124765A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP3253866B1 (en)	2024-12-04
WO2016124765A1 (en)	2016-08-11
EP3253866A1 (en)	2017-12-13
US20190024065A1 (en)	2019-01-24
AU2016214301B2 (en)	2022-05-19
AU2016214301A1 (en)	2017-08-24

Publication	Publication Date	Title
EP3253866C0 (en)	2024-12-04	GENETICALLY MANIPULATED PRIMARY HEMATOPOETIC CELLS BY SLOW RELEASE OF NUCLEIC ACIDS USING NANOPARTICLES
EP3532075A4 (en)	2020-07-08	VIRAL METHOD FOR PRODUCING GENETICALLY MODIFIED CELLS
HUE062646T2 (en)	2023-11-28	Enhancement of CAR-modified T cells by nucleic acid vaccination
HUE071193T2 (en)	2025-08-28	Early post-transfection isolation of cells (EPIC) for the production of biologics
DK3341482T3 (en)	2022-08-15	ARTIFICIAL NUCLEIC ACID MOLECULES
HUE047175T2 (en)	2020-04-28	Methods for studying nucleic acids
IL261710A (en)	2018-10-31	Production of antigen-specific t cells
PL3118311T3 (en)	2019-09-30	ANTISENSIVE NUCLEIC ACID
DK3329012T3 (en)	2021-10-11	Spatial mapping of nucleic acid sequence information
EP3500956C0 (en)	2025-01-15	DESIGN OF LATTICE STRUCTURES FOR ADDED MANUFACTURING
DK3620534T3 (en)	2021-12-06	CRISPR-CAS NUCLEIC ACID COMPOSITIONS-TARGETING NUCLEIC ACIDS
PL3394248T3 (en)	2021-09-13	COMPOSITION OF DENDRITIC CELLS
DK3242903T3 (en)	2021-09-27	COMPOSITIONS FOR INTRODUCING NUCLEIC ACID INTO CELLS
DK3094974T3 (en)	2019-05-27	IDENTIFICATION OF THE CONDITIONS OF FUNCTIONAL CELLS
DK3785799T3 (en)	2023-03-06	METHODS OF MANUFACTURE FOR WATER DISPERSIBLE ASSAYS
HUE049356T2 (en)	2020-09-28	Mammalian cells expressing cytomegalovirus antigens
HUE063273T2 (en)	2024-01-28	Production of heteromultimeric proteins using mammalian cells
DK3166612T3 (en)	2019-09-23	METHOD OF PREPARING 4-ALCOXY-3-HYDROXY-PICOLIC ACID
DK3262161T3 (en)	2021-09-13	Recombinant host cells for the production of 3-hydroxypropionic acid
DK3221918T3 (en)	2021-03-08	PROCEDURE FOR MELT-FREE RECYCLING OF LEAD ACID BATTERIES
EP3498724A4 (en)	2020-03-18	NUCLEIC ACID COMPLEX
EP3494131C0 (en)	2024-09-18	IMPROVED METHODS FOR THE PRODUCTION OF POLYNUCLEOTIDE LIBRARIES IN VACCINIA VIRUS/EUKARYOTIC CELLS
DK3242955T3 (en)	2020-08-03	MODELING RIBOSOM DYNAMICS TO OPTIMIZE HETEROLOG PROTEIN PRODUCTION
DK3166923T3 (en)	2023-04-11	PROCESS FOR THE PRODUCTION OF SUBSTITUTED PHENYLALKANES
DE112015000494T8 (en)	2016-11-17	Use of a solid state cell

Legal Events

Date	Code	Title	Description
2017-08-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2017-11-10	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2017-11-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-12-13	17P	Request for examination filed	Effective date: 20170803
2017-12-13	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-12-13	AX	Request for extension of the european patent	Extension state: BA ME
2018-05-16	DAV	Request for validation of the european patent (deleted)
2018-05-16	DAX	Request for extension of the european patent (deleted)
2019-01-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-02-13	17Q	First examination report despatched	Effective date: 20190114
2020-10-21	RIN1	Information on inventor provided before grant (corrected)	Inventor name: DUCHATEAU, PHILIPE Inventor name: DELACOTE, FABIEN
2024-07-01	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2024-07-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2024-07-31	INTG	Intention to grant announced	Effective date: 20240702
2024-10-30	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2024-11-01	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2024-11-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2024-12-04	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-12-04	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2024-12-13	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2024-12-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602016090485 Country of ref document: DE
2025-01-01	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2025-02-12	U01	Request for unitary effect filed	Effective date: 20250107
2025-03-05	U07	Unitary effect registered	Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20250131
2025-04-11	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204
2025-04-16	U20	Renewal fee for the european patent with unitary effect paid	Year of fee payment: 10 Effective date: 20250312
2025-04-17	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204
2025-04-23	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250304
2025-04-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250305
2025-04-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20250207 Year of fee payment: 10
2025-04-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250304
2025-07-03	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204
2025-07-09	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204
2025-07-14	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250404
2025-07-25	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204
2025-07-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204
2025-09-15	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241204
2025-09-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2025-10-10	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2025-10-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2025-10-21	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20250228
2025-11-12	26N	No opposition filed	Effective date: 20250905